कंपनी का अवलोकन
Accuray Incorporated is a specialized entity within the healthcare sector that focuses on the design, development, manufacturing, and commercialization of radiosurgery and radiation therapy systems used for tumor treatment across a global footprint including the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. Operating specifically within the medical devices industry, the company's activities are integral to the broader healthcare infrastructure, providing critical therapeutic equipment for oncological procedures. The enterprise demonstrates a significant operational scale, evidenced by a market capitalization of $50.01M and an annual revenue stream of $436.97M, supported by a workforce of 990 employees. These financial dimensions indicate that while the company holds a substantial position in generating revenue relative to its market valuation, the market cap suggests a smaller-scale enterprise compared to large-cap peers, reflecting a specific niche positioning within the medical technology landscape.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months reveal a revenue of $436.97M, which is contrasted by a net income of -$35,622,000 and an EBITDA of -$1,700,000. The substantial disparity between the reported revenue and the negative net income highlights a cost structure where operating expenses and other deductions significantly exceed the gross profits generated from sales. Free cash flow stands at -$803,500, indicating that the company is currently burning cash, which limits its immediate financial flexibility and ability to fund operations or investments without external financing. Profitability is further analyzed through three distinct margin metrics: a gross margin of 27.8%, an operating margin of -5.4%, and a profit margin of -8.2%. The positive gross margin suggests that the core production and sales of radiation systems are profitable, while the negative operating and profit margins indicate that overhead costs and non-operating expenses are eroding earnings to a material degree. Regarding balance sheet strength, the company holds $41.30M in cash against $174.23M in total debt, resulting in a debt-to-equity ratio of 326.14. This leverage structure signifies a highly leveraged balance sheet where debt obligations substantially outweigh equity, posing potential risks in a rising interest rate environment. Liquidity is assessed via a current ratio of 1.47, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, though the buffer is not excessively large. Finally, return metrics such as a return on equity of -70.3% and a return on assets of -1.2% reveal that management has not been effective in generating positive returns on the capital invested in the business, signaling ongoing operational challenges.
मूल्यांकन आकलन
Valuation multiples for Accuray Incorporated present a complex picture due to the negative earnings profile, with a trailing P/E ratio listed as N/A and a forward P/E of -14.03. The negative forward P/E implies that analysts or the market expects earnings to remain negative or for the company to incur further losses in the near future, rather than a path toward immediate profitability. The price-to-book ratio is calculated at 0.94, indicating that the market values the company at roughly 94% of its net asset value, which often suggests a market discount relative to the underlying book value of its assets. Alternative valuation metrics such as a price-to-sales ratio of 0.11 and an EV/EBITDA of -107.61 suggest that investors are pricing the stock based on revenue multiples rather than earnings power, a common practice for growth or distressed companies. The stock's price volatility is contextualized by its 52-week high of $2.10 and 52-week low of $0.33; depending on the current trading price, the stock is trading at a specific percentage below the 52-week high, reflecting significant price fluctuation over the past year. The beta value of 1.32 indicates that the stock is more volatile than the broader market, meaning that price movements in ARAY are expected to be amplified relative to general market index changes.
Growth & Income
The growth profile of the company is characterized by a revenue growth rate of -12.0% year-over-year, while earnings growth is listed as N/A due to the lack of positive earnings history. The negative revenue growth indicates a contraction in sales, suggesting a challenging market environment or a decline in demand for its radiation therapy systems. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is not returning capital to shareholders through cash distributions. Instead of paying dividends, the company retains its earnings—however negative they may be—and reinvests them into research, development, or debt management in an attempt to stabilize operations. Consequently, the overall growth and income profile is defined by revenue contraction and a complete absence of dividend income, forcing investors to rely solely on potential future equity appreciation or a turnaround in profitability.